TUCSON, Ariz.--(BUSINESS WIRE)--HTG Inc., a provider of novel array-based gene expression assay technology and services for the life sciences industry, today announced results from a study measuring gene expression on marker genes have been published in the August 2006 issue of Toxicology in Vitro. The study examined the feasibility of obtaining higher throughput results using the quantitative Nuclease Protection Assay (qNPA(TM)) method versus the standard PCR-based testing approach in testing 12 specific gene markers of drug-induced phospholipidosis on HepG2 cells. The published data show that the in vitro screening assay for compound-induced phospholipidosis should be transferable from a PCR-based assay to HTG’s qNPA, a higher throughput method. Hiroshi Sawada, Takeda Pharmaceutical Company Limited in Osaka, Japan is the lead author of the article.
